ArticleReviews in cardiovascular medicine2025
Impact of Completeness of Revascularization on Long-Term Outcomes in Patients With Post-Infarction Ventricular Septal Rupture.
Article in Reviews in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ventricular septal rupture (VSR) is a life-threatening complication of myocardial infarction. While surgical repair is regarded as the definitive treatment, the optimal approach to revascularization remains uncertain. This study aims to evaluate the effects of infarct-related artery (IRA) revascularization and the completeness of revascularization on long-term survival and the incidence of major adverse cardiovascular and cerebrovascular events (MACCE) in patients with VSR. Methods: This retrospective study analyzed 132 VSR patients who underwent surgical repair at the Fuwai Hospital from 2004 to 2022. Patients were categorized based on whether they received IRA revascularization. For those with multi-vessel disease (MVD), revascularization was classified as complete or incomplete. The primary outcome was all-cause mortality, with a mean follow-up of 77.8 months (median 71.0 months). The secondary outcome was MACCE. Results: Of the 132 patients, 28 did not undergo IRA revascularization. Kaplan-Meier analysis showed similar all-cause mortality and MACCE rates between patients with and without IRA revascularization. Adjusted Cox regression confirmed no significant association between IRA revascularization and long-term mortality (adjusted hazard ratio [aHR], 0.62; 95% CI: 0.22-1.79) or MACCE (aHR, 1.30; 95% CI: 0.52-3.27). These findings were consistent across both single-vessel and MVD patients. Among the 84 MVD patients, 53 underwent complete revascularization. Patients with complete revascularization had a lower incidence of MACCE (aHR, 0.26; 95% CI: 0.10-0.67) compared to those with incomplete revascularization, although no significant difference in mortality was observed (aHR, 0.57; 95% CI: 0.17-1.85). Conclusions: IRA revascularization does not affect long-term survival or MACCE rates in VSR patients. However, complete revascularization significantly reduces the risk of MACCE in patients with MVD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.